机构:[1]Collaborat Hebei Med Univ, Coll Forens Med, Innovat Ctr Forens Med Mol Identificat, Hebei Key Lab Forens Med, Shijiazhuang, Hebei, Peoples R China[2]Hebei Med Univ, Hosp 4, Dept Surg 2, Shijiazhuang, Hebei, Peoples R China临床科室外二科河北医科大学第四医院[3]Hebei Med Univ, Chinese Acad Med Sci, Res Unit Digest Tract Microecosyst Pharmacol & Tox, Shijiazhuang, Hebei, Peoples R China[4]China Pharmaceut Univ, Nanjing, Peoples R China[5]Hebei Med Univ, Inst Basic Med, Dept Pathogen Biol, Shijiazhuang, Peoples R China[6]Hebei Med Univ, Hosp 2, Dept Surg, Shijiazhuang, Hebei, Peoples R China
Introduction: The majority of individuals diagnosed with advanced colorectal cancer (CRC) will ultimately acquire resistance to 5-FU treatment. An increasing amount of evidence indicates that aerobic glycolysis performs a significant function in the progression and resistance of CRC. Nevertheless, the fundamental mechanisms remain to be fully understood.Methods: Proteomic analysis of 5-FU resistant CRC cells was implemented to identify and determine potential difference expression protein.Results: These proteins may exhibit resistance mechanisms that are potentially linked to the process of aerobic glycolysis. Herein, we found that nucleolar protein 58 (NOP58) has been overexpressed within two 5-FU resistant CRC cells, 116-5FuR and Lovo-5FuR. Meanwhile, the glycolysis rate of drug-resistant cancer cells has increased. NOP58 knockdown decreased glycolysis and enhanced the sensitivity of 116-5FuR and Lovo-5FuR cells to 5FU.Conclusion: The proteomic analysis of chemoresistance identifies a new target involved in the cellular adaption to 5-FU and therefore highlights a possible new therapeutic strategy to overcome this resistance.
基金:
Key Science and Technology Research project of Hebei Health Commission [20210054, 20220145]; National Science Foundation of China [82272909, 82304360]; CAMS Innovation Fund for Medical Sciences [2019-I2M-5-055]
第一作者机构:[1]Collaborat Hebei Med Univ, Coll Forens Med, Innovat Ctr Forens Med Mol Identificat, Hebei Key Lab Forens Med, Shijiazhuang, Hebei, Peoples R China[2]Hebei Med Univ, Hosp 4, Dept Surg 2, Shijiazhuang, Hebei, Peoples R China[3]Hebei Med Univ, Chinese Acad Med Sci, Res Unit Digest Tract Microecosyst Pharmacol & Tox, Shijiazhuang, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Collaborat Hebei Med Univ, Coll Forens Med, Innovat Ctr Forens Med Mol Identificat, Hebei Key Lab Forens Med, Shijiazhuang, Hebei, Peoples R China[2]Hebei Med Univ, Hosp 4, Dept Surg 2, Shijiazhuang, Hebei, Peoples R China[3]Hebei Med Univ, Chinese Acad Med Sci, Res Unit Digest Tract Microecosyst Pharmacol & Tox, Shijiazhuang, Hebei, Peoples R China[5]Hebei Med Univ, Inst Basic Med, Dept Pathogen Biol, Shijiazhuang, Peoples R China[6]Hebei Med Univ, Hosp 2, Dept Surg, Shijiazhuang, Hebei, Peoples R China
推荐引用方式(GB/T 7714):
Wang Feifei,Yu Bin,Yu Quanyong,et al.NOP58 induction potentiates chemoresistance of colorectal cancer cells through aerobic glycolysis as evidenced by proteomics analysis[J].FRONTIERS IN PHARMACOLOGY.2023,14:doi:10.3389/fphar.2023.1295422.
APA:
Wang, Feifei,Yu, Bin,Yu, Quanyong,Wang, Guanglin,Li, Baokun...&Cong, Bin.(2023).NOP58 induction potentiates chemoresistance of colorectal cancer cells through aerobic glycolysis as evidenced by proteomics analysis.FRONTIERS IN PHARMACOLOGY,14,
MLA:
Wang, Feifei,et al."NOP58 induction potentiates chemoresistance of colorectal cancer cells through aerobic glycolysis as evidenced by proteomics analysis".FRONTIERS IN PHARMACOLOGY 14.(2023)